Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 771 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disease Sickle Cell Anemia Clear all
Completed Phase 1 Interventional

Oral Ketamine for Treatment of Vaso-Occlusive Pain

NCT05378555
View directory record Official record
Conditions
Vaso-occlusive Crisis
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

NCT01895361
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SelG1, Placebo
Drug
Lead sponsor
Reprixys Pharmaceutical Corporation
Industry
Eligibility
16 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Not applicable Interventional

COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease

NCT05998824
View directory record Official record
Conditions
Sickle Cell Disease, COVID-19 Vaccine, Vaccine Hesitancy
Interventions
SCD-specific COVID-19 vaccination information (SCVI) video
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 100 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 29, 2026, 4:21 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Study of Blood Platelets in Sickle Cell Disease

NCT00226083
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
7 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

NCT00040469
View directory record Official record
Conditions
Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
Interventions
Campath -1H, Dilantin, Busulfan, Cyclophosphamide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 29, 2026, 4:21 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

NCT05031780
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Mitapivat, Mitapivat-matching placebo
Drug · Other
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
16 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

NCT04817670
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg, Placebo BID, Placebo TID
Drug
Lead sponsor
Vifor (International) Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Not applicable Interventional

Use of Mobile Technology for Intensive Training in Medication Management

NCT02133560
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Video recording, Medication Administration Log, Education
Behavioral
Lead sponsor
Duke University
Other
Eligibility
5 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 29, 2026, 4:21 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

NCT02973360
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Docosahexaenoic Acid, Placebo
Drug
Lead sponsor
Micelle BioPharma Inc
Industry
Eligibility
5 Years to 17 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Oakland, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Not applicable Interventional

The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.

NCT04691323
View directory record Official record
Conditions
Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C
Interventions
HU-Go app
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 21 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

NCT05904093
View directory record Official record
Conditions
Sickle Cell Disorders, Sickle Cell Disease, Hemoglobin S, Hb-SS Disease, Disease Sickle Cell Anemia
Interventions
Fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Active, not recruiting Not applicable Interventional

Sickle Cell Children's Exercise Study (SuCCESs)

NCT06074198
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SuCCESs
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional

Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

NCT06184126
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Acute Pain
Interventions
Virtual Reality Headset and Hand-Held Controllers, Blindfolding and Noise Cancelling
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 29, 2026, 4:21 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

NCT03943615
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Gene Therapy for Sickle Cell Disease

NCT02247843
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
βAS3-FB vector transduced peripheral blood CD34+ cells
Biological
Lead sponsor
Donald B. Kohn, M.D.
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 4 Interventional

Low Dose Ketamine and Acute Pain Crisis

NCT04330183
View directory record Official record
Conditions
Sickle Cell Crisis
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

NCT00532883
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 29, 2026, 4:21 PM EDT
Completed No phase listed Observational

Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD

NCT00228631
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
6 Months to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Imatinib for Pain in Sickle Cell Anemia

NCT03997903
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Imatinib Mesylate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 25 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 1 Interventional

Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease

NCT02012777
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
propranolol
Drug
Lead sponsor
University of Miami
Other
Eligibility
10 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Not applicable Interventional

Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App

NCT04675645
View directory record Official record
Conditions
Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C
Interventions
HU-Go app
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 25 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

NCT00940901
View directory record Official record
Conditions
Sickle Cell Disease, Priapism
Interventions
sildenafil, placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 45 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 29, 2026, 4:21 PM EDT
Not listed Not applicable Interventional

FOCUS for Pediatric Sickle Cell Disease and Cancer

NCT04075877
View directory record Official record
Conditions
Pediatric Cancer, Sickle Cell Disease, Quality of Life, Depressive Symptoms, Coping Skills
Interventions
FOCUS
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
12 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 29, 2026, 4:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

Non-Myeloablative Conditioning and Bone Marrow Transplantation

NCT01850108
View directory record Official record
Conditions
Sickle Cell Disease, Hemoglobinopathies
Interventions
Thymoglobulin, Fludarabine, Cyclophosphamide (CTX), Mesna, Sirolimus, Mycophenolate mofetil (MMF), Bone marrow transplantation, Total body irradiation
Drug · Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
1 Year to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 29, 2026, 4:21 PM EDT